The safety and efficacy of combination yv-butyl-deoxynojirimycin (Sc-48334) and zidovudine in patients with hiv-1 infection and 200-500 cd4 cells/mm3

Margaret A. Fischl, Lionel Resnick, Robert Coombs, Alton B. Kremer, John C. Pottage, Robert J. Fass, Kenneth H. Fife, William G. Powderly, Ann C. Collier, Richard L. Aspinall, Susan L. Smith, Kenneth G. Kowalski, Carl Bertil Wallemark

Research output: Contribution to journalArticle

104 Scopus citations
Original languageEnglish (US)
Pages (from-to)139-147
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume7
Issue number2
StatePublished - Feb 1994

Keywords

  • Combination therapy
  • Glucosidase inhibitor
  • Hiv
  • N-butyl-deoxynojirimvein (sc-48334)

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Fischl, M. A., Resnick, L., Coombs, R., Kremer, A. B., Pottage, J. C., Fass, R. J., Fife, K. H., Powderly, W. G., Collier, A. C., Aspinall, R. L., Smith, S. L., Kowalski, K. G., & Wallemark, C. B. (1994). The safety and efficacy of combination yv-butyl-deoxynojirimycin (Sc-48334) and zidovudine in patients with hiv-1 infection and 200-500 cd4 cells/mm3. Journal of Acquired Immune Deficiency Syndromes, 7(2), 139-147.